Barrett\'s oesophagus (BO) is an acquired condition in which the normal squamous lining of the distal oesophagus is replaced by a specialised intestinal metaplastic (IM) columnar epithelium ([@bib33]). Barrett\'s oesophagus is found in ∼6--12% of all upper gastrointestinal endoscopies ([@bib23]) and in an estimated 1.6% of individuals in Western populations. Known risk factors for BO include gastroesophageal reflux disease (GERD), male sex, age over 50 years, Caucasian ethnicity, obesity (especially with a central/visceral fat distribution) and smoking ([@bib13]; [@bib22]).

Barrett\'s oesophagus is a multistage disease in which a minority of patients progress from IM through the stages of low-grade dysplasia (LGD) to high-grade dysplasia (HGD) and to oesophageal adenocarcinoma (OAC; [@bib12]). Recent population-based data indicate that patients with BO without dysplasia have an ∼0.5% annual risk of progression from BO to OAC ([@bib24]; [@bib17]). This risk is higher for patients with HGD, who may have a 6% or higher annual risk of progressing to cancer ([@bib39]). Oesophageal adenocarcinoma is a highly fatal cancer, which has increased six-fold in incidence over the past three decades ([@bib19]).

Recent data indicate that endoscopic surveillance may correlate with earlier stage diagnosis and improved survival from cancer ([@bib3]). For this reason, guidelines on the management of BO ([@bib40]; [@bib22]) generally recommend endoscopic surveillance with histopathological assessment of dysplasia in four-quadrant random biopsies taken every 2 cm, in addition to targeted biopsies taken from macroscopically visible lesions (so-called Seattle protocol).

There are significant problems with the endoscopic surveillance of patients with BO, including sampling error and variation in the histopathological interpretation of the degree of dysplasia ([@bib35]; [@bib28]). In addition, OAC can also develop in the interval between surveillance endoscopies ([@bib38]). Further, only 5--7% of patients presenting with OAC have a previous diagnosis of BO ([@bib18]; [@bib3]).

These deficiencies in current management have stimulated a search for biomarkers to improve both the early detection of OAC and the identification of patients with BO who are at high risk of progressing OAC. So far no biomarkers have proven adequate for routine clinical practice ([@bib44]; [@bib22]). A blood biomarker would have several advantages over the current subjective histologic interpretation of endoscopic tissue biopsies, including being less invasive and safer, less expensive and potentially applicable for at-risk population screening.

Macrophage inhibitory cytokine 1 (MIC-1, also known as growth differentiation factor 15, GDF15), is a divergent member of the transforming growth factor-*β* (TGF-*β*) superfamily, which is not highly expressed under normal conditions, other than in the placenta ([@bib4]; [@bib20]). Its expression is increased by injury, inflammation or malignancy and it is involved in the pathogenesis of a number of disease including cancer and cardiovascular diseases ([@bib6]).

Macrophage inhibitory cytokine 1/growth differentiation factor 15 expression is increased in most cancers including those of the prostate, colon, ovary and breast ([@bib48]; [@bib16]), and various cancer cell lines are known to secrete large amounts of MIC-1/GDF15 ([@bib2]; [@bib43]). In many cancers, MIC-1/GDF15 serum levels are associated with histopathological cancer grade, stage and extent of disease, and have been reported as predictors of disease progression in prostate, ovary and colorectal cancer ([@bib2]). Macrophage inhibitory cytokine 1/growth differentiation factor 15 may also have a role as a clinical biomarker in multiple myeloma, oral squamous cancer and bladder cancer ([@bib10], [@bib9]; [@bib15]; [@bib47]; [@bib8]; [@bib14]). Serum levels of MIC-1/GDF15 are reported to increase during the progression of colorectal cancer ([@bib10]) and serum MIC-1/GDF15 measurement is a validated prospective biomarker of the presence of colorectal polyps and cancer, indicating that it has potential as a screening tool in these diseases ([@bib8]).

The above data suggest that MIC-1/GDF15 may be useful in the management of BO and OAC. We investigated MIC-1/GDF15 plasma and tissue levels in patients with different stages of BO to assess the potential of MIC-1/GDF15 quantification as a biomarker for diagnosis, for prediction of progression in patients with BO, as well as for diagnosis and prognosis in patients with OAC.

Materials and Methods
=====================

Study design, study population and specimen collection
------------------------------------------------------

We performed a retrospective diagnostic case--control analysis to examine the associations between (a) MIC-1/GDF15 tissue mRNA expression and normal oesophagus (NE), BO, LGD and OAC; (b) MIC-1/GDF15 plasma protein levels and NE, BO, LGD and OAC; and (c) to test the association between MIC-1/GDF15 plasma levels and overall survival in patients with OAC. An analysis of the performance of MIC-1/GDF15 tissue and plasma levels to distinguish between NE, BO, LGD and OAC was also conducted.

The NE, BO and LGD tissues and blood samples were collected at endoscopies performed at St Vincent\'s Hospital, Sydney, Australia. These were obtained from patients prospectively enroled in an Australia-wide research collaboration entitled PROBE-NET: Progression of Barrett\'s Esophagus to Esophageal Adenocarcinoma Network. The OAC specimens were either obtained from patients at St Vincent\'s Hospital or from patients who had been enroled in the population-based case--control Australian Cancer Study through the QIMR Berghofer Medical Research Institute (QIMRB; [@bib49]). All tissues were formalin fixed and paraffin embedded. The pathological diagnoses were established by pathologists at the respective host institutions. Sections from tissue blocks for mRNA extraction were chosen after reviewing the histopathologic reports and haematoxylin and eosin (H&E) stained slides to confirm the presence of the correct diagnoses. Barrett\'s oesophagus was diagnosed when there was any length of columnar mucosa in the tubular oesophagus, with IM containing goblet cells on histopathological examination.

Patient plasma samples were collected at study recruitment, centrifuged at 1800 **g**, and the resultant plasma stored at −80 °C until further use. For the analysis of plasma MIC-1/GDF15 levels as a prognostic marker for OAC survival, we used pretreatment samples from an independent cohort of 23 patients with OAC from the Australian Cancer Study ([@bib49]) and 7 patients treated at St Vincent\'s Hospital, Sydney. All subjects were treated by oesophagectomy with curative intent and received no preoperative chemotherapy or radiotherapy. Only patients with complete clinicopathological and follow-up data (*n*=27) were included in the survival analysis.

Institutional review board approval for this study was obtained at all collaborating institutions and all patients provided written informed consent.

RNA isolation
-------------

All tissues processed were cut from formalin-fixed, paraffin-embedded tissue blocks. Two 7-*μ*m sections were cut for RNA extraction, which was performed using the Qiagen FFPE RNeasy kit, (cat \# 74404, Qiagen, Valencia, CA, USA) following the manufacturer\'s protocol. Satisfactory RNA yield and quality were confirmed using the BioSpec-nano spectrophotometer (Shimadzu Scientific Instruments, Sydney, Australia).

Multiplexed tandem PCR
----------------------

Multiplexed tandem PCR (MT-PCR) was used to quantitate the mRNA expression levels of MIC-1/GDF15 and a reference gene, NONO ('non-POU domain-containing, octamer-binding (NONO), transcript variant 2\' NM_007363), using the Rotor-Gene 6000 real-time quantitative PCR system (Corbett Life Sciences/Qiagen, Sydney, Australia), as previously described ([@bib41]; [@bib5]). Briefly, MT-PCR is performed in two stages. In the first stage, isolated RNA is converted into cDNA and amplified using gene-specific primers ('outer\' primers). In the second step, the product from stage one is used as a template for PCRs run in a 72-well disc-containing single-gene primers ('inner\' primers) in each well. Primers were designed using Primer 3 software modified by AusDiagnostics Pty. Ltd. (AusDiagnostics, Alexandria, New South Wales, Australia). All primer pairs spanned an intron--exon boundary and all samples were run in duplicate. Correct product size and integrity was verified on a Bioanalyzer DNA separation chip (Agilent Technologies, Forest Hill, Victoria, Australia). The relative mRNA expression values were calculated as the ratio of the raw MIC-1/GDF15 mRNA values to the control gene NONO, with the expression of NONO set to a fixed level (1000).

MIC-1/GDF15 enzyme-linked immunosorbent assay
---------------------------------------------

Plasma MIC-1/GDF15 levels were measured using a validated sandwich enzyme immunoassay, as described previously ([@bib30]; [@bib21]; [@bib7]). Briefly, mouse mAb 26G6H6 was used for antigen capture and sheep PAb 233-P was used for detection. The human MIC-1/GDF15 (hMIC-1/GDF15) plasma concentration was determined by reference to a standard curve, which was constructed using recombinant hMIC-1/GDF15. All samples were run in duplicate. To ensure reproducibility, the coefficient of variation for all readings was below 10%. Assay performance was further monitored using standard diagnostic laboratory quality control procedures.

Statistical analysis
--------------------

Continuous variables were compared using *t*-test statistics, Wilcoxon rank-sum test, one-way analysis of variance and the Kruskal--Wallis test where appropriate. Where necessary, log2 transformation of mRNA relative expression and plasma ELISA values was performed to achieve normal distribution for these analyses. Differences between proportions derived from categorical data were analysed using Pearson\'s chi-squared test or Fisher\'s exact test.

The area under the curve (AUC) of the receiver operator characteristic (ROC) curve and 95% confidence interval (CI) was calculated to explore the performance of MIC-1/GDF15 tissue and plasma levels to discriminate between patient pathology groups for three distinct potential clinical uses as follows: (i) to explore the potential of MIC-1/GDF15 tissue and/or plasma measurement as a screening test for OAC, we assessed discrimination between OAC *vs* non-OAC patients (NE, BO and LGD); (ii) to assess the potential of MIC-1/GDF15 measurement as a triage test to rule out low-risk patients who do not require further intervention or endoscopy surveillance, we assessed discrimination between NE and BO *vs* LGD and OAC; and (iii) to assess the performance of tissue MIC-1/GDF15 gene expression and plasma levels as a diagnostic test to identify patients at high risk of developing OAC, we assessed discrimination between OAC and its respective 'high\'-risk population (BO IM+LGD). For each of these potential biomarker purposes, the optimal cut point for MIC-1/GDF15 was selected by the Youden\'s index ([@bib50]) to inform future validation studies and the sensitivity, specificity at this cut point was reported with 95% CI.

As MIC-1/GDF15 plasma values are known to correlate with nutritional status and BMI ([@bib25]; [@bib6]), BMI was recorded for all patients providing plasma samples, and we performed a separate analysis for patients who were non-obese and not underweight (BMI 18.5--29.9 kg m^−2^) as defined by the WHO ([@bib45]).

The Kaplan--Meier method was used to compare survival times for patients classified by MIC-1/GDF15 cutoff levels and differences in survival times were compared using the log-rank test. A Cox proportional hazards model was used to identify independent factors associated with mortality. Only patients with complete clinicopathological and survival data were included for survival analysis (*n*=27). Data are presented as mean (s.d.), median (interquartile range (IQR)) and OR/HR (95% CI), where applicable. All *P*-values \<0.05 were regarded as statistically significant. For ROC curve AUC analysis, the *P*-value indicates the probability that an observed sample AUC is found when the true AUC is 0.5 (no difference between groups). If the *P*-value is \<0.05, it can be concluded that the AUC is statistically significantly different from 0.5 providing statistical evidence that the biomarker has the ability to distinguish between the two groups ([@bib50]; [@bib31]).

All statistical analyses were performed using R Statistical Packages ([@bib34]) and graphing/plotting was performed in Prism (GraphPad Prism version 6.0c for Mac OS X, GraphPad Software, San Diego, California, USA).

Results
=======

Patients and tissues
--------------------

Demographic data for the 138 patients included in this study are shown in [Table 1](#tbl1){ref-type="table"}. Briefly, 45 patients (33%) who underwent clinically indicated upper endoscopy showing no BO and who had no history of GERD were included as healthy controls and provided normal squamous oesophageal tissue and baseline blood samples. Thirty-seven patients (27%) had histologically confirmed BO with IM but no dysplasia, and 16 patients (12%) had BO with LGD. Of the 40 patients with OAC, most had AJCC stage I--IIB disease (73%), whereas 8 patients were stage III (20%) and 1 was stage IV (3%). Despite chart review the correct tumour stage could not be assessed in two patients (5%) due to incomplete clinical data.

MIC-1/GDF15 tissue mRNA expression analysis
-------------------------------------------

MIC-1/GDF15 was significantly overexpressed in BO, LGD and OAC when compared to normal squamous oesophagus ([Figure 1A](#fig1){ref-type="fig"}). Median relative mRNA expression of MIC-1/GDF15 increased 25-fold from NE to BO (44.2 to 1092.0; *P*\<0.001), with median expression levels higher in BO--LGD compared to BO, although this difference was not statistically significant (1092.0 *vs* 1185; *P*=0.43). Macrophage inhibitory cytokine 1/growth differentiation factor 15 expression was 47 times higher in OAC compared to NE (2249.0 *vs* 44.2; *P*\<0.001), and was also significantly higher in OAC compared to BO IM (2249 *vs* 1092; *P*=0.039).

The AUC for the discriminative performance of MIC-1/GDF15 gene expression to distinguish between OAC and non-OAC (NE, BO and LGD) was 0.82 (95% CI 0.70--0.93; *P*\<0.001). For this analysis, the optimal cut point for relative MIC-1/GDF15 mRNA expression was 961, which yielded a sensitivity of 88% (95% CI 68--97%) and specificity of 64% (95% CI 44--81%) for the detection of OAC ([Table 2](#tbl2){ref-type="table"}).

The AUC for the discriminative performance of MIC-1/GDF15 to rule out LGD or OAC was 0.86 (95% CI 0.73--0.96; *P*\<0.001). For this analysis, the optimal cut point for relative MIC-1/GDF15 mRNA expression was 720, which yielded a sensitivity of 94% (95% CI 79--99%) and specificity of 71% (95% CI 48--89% [Table 2](#tbl2){ref-type="table"}). This result indicates that if MIC-1/GDF15 mRNA expression values are low, the presence of OAC and/or dysplastic Barrett\'s disease can be ruled out with a 6% false-negative rate (95% CI 1--21%).

The diagnostic performance of tissue MIC-1/GDF15 gene expression to distinguish between OAC and the at-risk population (BO IM, LGD) was AUC 0.70 (95% CI 0.51--0.88; [Figure 1B](#fig1){ref-type="fig"}) with a sensitivity of 63% (95% CI 41--81%) and specificity of 77% (95% CI 50--93%) at the optimal cut point of 1768 ([Table 2](#tbl2){ref-type="table"}).

MIC-1/GDF15 plasma analysis
---------------------------

Median MIC-1/GDF15 plasma values were significantly higher in patients with OAC compared to healthy controls (1018 *vs* 606 pg ml^−1^; *P*\<0.001), patients with BO (1018 *vs* 783 pg ml^−1^; *P*=0.015) and patients with BO with LGD (735 pg ml^−1^, *P*=0.027; [Figure 2A](#fig2){ref-type="fig"}).

The discriminative performance of plasma MIC-1/GDF15 levels to distinguish between NE, BO, LGD and OAC is shown in [Figure 2B](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}. For example, for use as a screening test, the AUC of plasma MIC-1/GDF15 levels for the detection of OAC *vs* non-malignant oesophageal findings (NE, BO and LGD) was 0.75 (95% CI 0.65--0.85; *P*\<0.001) with MIC-1/GDF15 plasma levels above an optimal cut point of 811 pg ml^−1^ yielding a sensitivity of 83% (95% CI 65--94%) and specificity of 62% (95% CI 50--74%) for the detection of OAC. However, the AUC for MIC-1/GDF15 plasma measurements as a triage test to rule out LGD or OAC did not indicate potential for discriminating between patient groups (data not shown).

In patients who were non-obese and not underweight (BMI 18.5--29.9 kg m^−2^) as defined by the WHO ([@bib45]), median MIC-1/GDF15 plasma levels were slightly lower for all patient groups except for those patients with OAC, where median plasma levels were in a similar range (1040.5 pg ml^−1^; *P*=0.85). [Figure 2C](#fig2){ref-type="fig"} summarises the findings of the plasma analysis when corrected for BMI.

The discriminative performance of plasma MIC-1/GDF15 levels corrected for BMI to distinguish between NE, BO, LGD and OAC is shown in [Figure 2D](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}. Briefly, non-obese patients with a MIC-1/GDF15 plasma value above the optimal cut point of 811 pg ml^−1^ were approximately four times more likely to have a malignant oesophageal finding than those with lower MIC-1/GDF15 plasma levels (AUC 0.85 (95% CI 0.76--0.95), sensitivity 84% (95% CI 64--95%) and specificity 80% (95% CI 65--90%)).

MIC-1/GDF15 plasma levels and overall survival in OAC
-----------------------------------------------------

Two patients were excluded from the survival analysis due to incomplete clinicopathological data. Patients were grouped into AJCC stages 1 and 2 in one group and stages 3 and 4 in another group.

There were no significant associations between MIC-1/GDF15 plasma levels and any of the following known prognostic factors: histopathological grade, T-stage, positive nodal status, higher tumour stage (data not shown).

There was a non-significant trend towards worse overall survival in patients with OAC and elevated levels of MIC-1/GDF15 (⩾1140 pg ml^−1^ (optimal cut point determined by ROC curve analysis); 47.5 *vs* 33.0 months, *P*=0.063; [Figure 3](#fig3){ref-type="fig"}). However, in a multivariable Cox proportional hazards model including the independent variables age, BMI, overall tumour stage and plasma MIC-1/GDF15 values ⩾1140 pg ml^−1^, both elevated plasma MIC-1/GDF15 levels (HR 3.87, 95% CI 1.01--14.75; *P*=0.048) and worse tumour stages (HR 13.85, 95% CI 2.31--83.23, *P*=0.004) were significant independent prognostic markers for mortality ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

In this novel study, we found evidence for an association between MIC-1/GDF15 tissue and plasma levels in patients with BO and OAC. This suggests that MIC-1/GDF15 could be evaluated further for its potential as a biomarker in this disease, with our results indicating a greater biomarker potential for measuring MIC-1/GDF15 in blood rather than tissues. A non-tissue, non-endoscopic biomarker or biomarker panel detectable in blood would offer a major advantage if it could replace the need for pathology classification of dysplasia. Although the presence of dysplasia in BO detected by histopathological examination of tissue specimens is the most informative current predictor of risk of progression to OAC, it is not a reliable tests as shown by the disturbing lack of agreement between pathologists and their interpretation of presence or severity of dysplasia ([@bib35]; [@bib38]). Histopathological examination of the primary tumour and resected lymph nodes along with radiologic tests is also the current basis of staging patients with OAC and determining prognosis, but similarly has limited accuracy. For example, ∼50% of patients assessed as having no lymph node involvement at diagnosis, and thus a good prognosis, will still die of their disease by 10 years ([@bib36]). Identifying predictive and prognostic biomarkers for BO and OAC is thus crucial to improve clinical care.

Our evaluation of MIC-1/GDF15 plasma quantification as a diagnostic test for OAC found that patients with high MIC-1/GDF15 plasma levels who were neither underweight nor obese were more than four times more likely to have OAC. This likelihood decreased by two-fold if obese or underweight patients were included in the analysis. This reduction may be explained by the confounding effect of the known relationship of MIC-1/GDF15 blood levels and BMI ([@bib25]; [@bib6]). This finding addresses a potential limitation of the clinical applicability of plasma MIC-1/GDF15 analysis for the diagnosis and monitoring of patients with Barrett\'s disease, as patients with BO usually have higher BMI and increased waist circumference ([@bib27]). Conversely, however, as elevated MIC-1/GDF15 serum levels are known to be associated with tumour-induced weight loss ([@bib46]; [@bib42]), patients with noted weight loss (despite the lack of dysphagia/reduced food intake) and elevated plasma MIC-1 levels may identify those at highest risk of bearing an oesophageal malignancy.

Others have shown the potential clinical use for MIC-1/GDF15 in blood for the diagnosis and/or monitoring of pancreatic, prostate, colon and thyroid cancers, especially when MIC-1/GDF15 is combined with other markers, as we anticipate would also be the case with OAC ([@bib26]; [@bib9]). In pancreatic cancer, for example, combining MIC-1/GDF15 serum levels with CA19-9 significantly improved the diagnosis of pancreatic cancer leading to a sensitivity of 70% and specificity of 85% ([@bib26]). In prostate cancer, the combination of serum MIC-1/GDF15 levels with prostate-specific antigen significantly improved the overall diagnostic specificity and shows great potential for monitoring of disease progression ([@bib9]).

In this study, we also found that elevated MIC-1/GDF15 plasma levels were an independent prognostic marker for reduced overall survival in patients, although the reliability of this finding is diminished by the small number of patients in this section (*n*=27). This finding was significant when MIC-1/GDF15 was included in a multivariable Cox proportional hazards model, which was adjusted for age, tumour stage and BMI. The patients in this study were treated by oesophagectomy alone in all but one case. Because no patient received neoadjuvant chemotherapy or radiotherapy, our findings are unlikely to be explained by variations in treatment or the effect of treatment on tumour biology.

Studies of patients with other malignancies have suggested that MIC-1/GDF15 is a marker of adverse prognosis as its blood levels increased with increasing histopathological grade, invasiveness and metastasis ([@bib29]; [@bib6]). However, in this study, we did not find a significant difference in plasma MIC-1/GDF15 levels between patients with lower *vs* higher stages of OAC. We believe this is most likely due to the limited number of patients with more advanced stages of the disease. Further studies are required to help resolve whether blood levels of MIC-1/GDF15 can help in OAC staging. A blood marker that can identify patients with locally limited but perhaps occult disseminated disease would potentially allow early allocation to more aggressive treatment strategies.

Our finding that elevated plasma MIC-1/GDF15 provides independent prognostic information contrasts with the only other report on MIC-1/GDF15 blood levels that included patients with OAC ([@bib37]). In this study, patients with elevated MIC-1/GDF15 levels showed reduced survival compared to those with lower MIC-1/GDF15 levels, but MIC-1/GDF15 was not an independent prognostic indicator. However, this study also included patients with oesophageal squamous, undifferentiated and neuroendocrine carcinoma, and 52% of the included cancers were not of oesophageal origin (oesophageal junction with undefined localisation or gastric cancer) leading to a more heterogeneous study population. In contrast to [@bib37] however, we did not have data on systemic inflammatory markers and were therefore not able to adjust for this in our Cox regression model.

In oesophageal tissue biopsies, we found that MIC-1/GDF15 mRNA levels were associated with the presence of BO as well as the stage of the disease (IM, LGD and OAC). These findings indicate it may have potential to aid in conventional histopathology methods. This could be explored in future studies by comparing MIC-1/GDF15 results with conventional methods to determine its clinical value for patient management. In particular, given the high clinical need to identify patients at risk of progression to OAC, our results suggest that it may be useful to explore tissue MIC-1/GDF15 levels in prospective studies of BO patients, in contrast to the cross-sectional design of the present study. It would also be useful to investigate through *in vivo* studies (which we have not performed), the correlation between MIC-1/GDF15 tissue and plasma levels in this disease, as in other malignancies the intracellular processing of MIC-1/GDF15 ultimately determines the relative amount of MIC-1/GDF that remains in the tumour microenvironment *vs* the amount diffusing into the systemic circulation. This additive predictive value has been demonstrated in prostate cancer stromal staining, where detection of proMIC-1/GDF15 was an important independent predictor of disease relapse ([@bib1], [@bib2]).

There are two possible explanations for our findings in tissues. First, the increased MIC-1/GDF15 levels in BO IM, BO--LGD and OAC may be linked to the inflammatory response of the oesophagus to severe GERD, as MIC-1/GDF15 is increased in response to multiple cellular stressors and following acute injury and/or inflammatory tissue changes ([@bib20]; [@bib48]; [@bib43]). Alternatively (or in addition) MIC-1/GDF15 levels may also signal neoplastic progression of BO to OAC, which is consistent with data in colon cancer, in which MIC-1/GDF15 levels increase with disease progression from normal to adenoma, carcinoma and metastatic disease ([@bib10]).

There are clear limitations to our findings. First, due to the relatively small sample size of the present study, the results presented must be interpreted with caution and require confirmation in future, larger well-described Barrett\'s/OAC patient cohorts. Second, tissue specimen sampling error may occur, a general problem in all studies using endoscopic biopsy specimens from patients with Barrett\'s disease ([@bib28]). By reviewing the histology of all specimens used prior to RNA extraction, we attempted to minimise non-uniformity in the tissue specimens used. Third, our estimates of sensitivity and specificity are drawn from a selective sample of patients presenting for endoscopy and therefore need to be interpreted with caution due to the potential for spectrum bias, which is associated with overestimates of test accuracy ([@bib32]). Lastly, MIC-1/GDF15 plasma levels are known to be influenced by the use of non-steroidal anti-inflammatory drugs (NSAIDs; [@bib8]), which in turn have been shown to influence oesophageal adenocarcinogenesis and the prognosis of patients affected by this cancer ([@bib11]). We did not have complete data on patients\' NSAID use and thus were not able to correct for this possible confounding factor.

In conclusion, however, this study provides evidence to suggest that blood MIC-1/GDF15 measurements may have a clinical role for diagnosis and monitoring of Barrett\'s disease spectrum. These findings need to be confirmed in larger prospective studies, in particular studies including serial MIC-1/GDF15 blood measurements in patients with different stages of BO to determine how dynamic changes in MIC-1/GDF15 levels may be used to inform patient management. Further, for patients already affected by OAC, blood levels of MIC-1/GDF15 may help provide additional prognostic information.
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![**Boxplot of tissue MIC-1/GDF15 mRNA expression analysis by pathology diagnosis.** Raw relative mRNA expression values are presented. Differences in relative gene expression values were calculated using Student\'s *t*-test following log2 transformation. Bold values indicates that these are statistically significant. Dot indicates outlier as is convention for presenting boxplot data.](bjc2015100f1){#fig1}

![**Boxplots of MIC-1/GDF15 plasma levels by pathology diagnosis and corresponding receiver operator characteristic (ROC) curves for performance analysis of tissue MIC-1/GDF15 plasma levels to discriminate patient groups.** (**A** and **B**) Show the analysis of the whole study cohort, whereas (**C** and **D**) depict the findings in the non-obese, non-underweight (as categorised by the WHO) patient population. Differences in plasma values were calculated using Student\'s *t*-test following log2 transformation. Data are presented untransformed as pg ml^−1^. Bold values indicates that these are statistically significant. Dot indicates outlier as is convention for presenting boxplot data. \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2015100f2){#fig2}

![Survival of OAC patients stratified by MIC-1/GDF15 plasma levels ⩾1140 pg ml^−1^ (as determined by ROC curve analysis).](bjc2015100f3){#fig3}

###### Clinical and pathologic characteristics of included patients

                                           **All (*****n*****=138)**   **mRNA analysis (*****n*****=53)**   **Plasma analysis (*****n*****=99)**                
  --------------------------------------- --------------------------- ------------------------------------ -------------------------------------- -------- ---- --------
  **Gender**                                                                                                                                                    
   Males                                              102                              74                                    42                      79     73     74
   Females                                            36                               26                                    11                      21     26     26
  Median age, years (range)                           60                             51--68                                  63                    55--74   61   51--68
  **Diagnosis**                                                                                                                                                 
   Normal oesophagus                                  45                               33                                    12                      23     33     33
   Barrett\'s oesophagus IM                           37                               27                                    10                      19     27     27
   Barrett\'s oesophagus with dysplasia               16                               12                                    7                       13     9      9
   Oesophageal adenocarcinoma                         40                               29                                    24                      45     30     30
  **TNM (7th edition)**                                                                                                                                         
   T1--2                                              31                               78                                    22                      92     23     77
   T3--4                                               7                               18                                   ---                     ---     7      23
   N1--3                                              11                               8                                     3                       13     10     33
   M+                                                  1                               3                                    ---                     ---     1      3
   Unknown T, N or M                                   2                               5                                     2                       8      0     ---
  **Tumour stage (AJCC 7th edition)**                                                                                                                           
   IA--B                                              14                               35                                    9                       38     11     37
   IIA                                                13                               33                                    10                      42     9      30
   IIB                                                 2                               5                                     2                       8      1      3
   IIIA--C                                             8                               20                                    1                       4      8      27
   IV                                                  1                               3                                    ---                     ---     1      3
   Unknown stage                                       2                               5                                     2                       8      0     ---
  Median survival, months (range)                     38                             18--51                                  34                    18--48   43   23--56

Abbreviations: AJCC=American Joint Committee on Cancer; IM=intestinal metaplasia; TNM=tumour, node and metastasis.

###### Discriminative performance of plasma MIC-1/GDF15 in predicting the presence of oesophageal pathologies

                                                                                          **Youden index**[a](#t2-fn2){ref-type="fn"}   **Cutoff point**[a](#t2-fn2){ref-type="fn"}  **AUC (95% CI)**     **Sensitivity (95% CI)**   **Specificity (95% CI)**   ***P*****-value**[b](#t2-fn3){ref-type="fn"}
  -------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------- -------------------------- -------------------------- ----------------------------------------------
  **Tissue mRNA (*****n*****=54)**                                                                                                                                                                                                                             
   Non-malignant *vs* OAC                                                                                    0.52                                           961                      0.82 (0.70--0.93)       0.88 (0.68--0.97)          0.64 (0.44--0.81)                          0.001
   NE+BO *vs* LGD+OAC                                                                                        0.65                                           720                      0.86 (0.73--0.96)       0.94 (0.79--0.99)          0.71 (0.48--0.89)                         \<0.001
   BO+LGD *vs* OAC                                                                                           0.39                                          1768                      0.70 (0.51--0.88)       0.63 (0.41--0.81)          0.77 (0.50--0.93)                           0.03
  **Plasma ELISA for all patients (*****n*****=99)**                                                                                                                                                                                                           
   Non-malignant *vs* OAC                                                                                    0.46                                           811                      0.75 (0.65--0.85)       0.83 (0.65--0.94)          0.62 (0.50--0.74)                         \<0.001
   NE *vs* BO+LGD+OAC                                                                                        0.35                                           705                      0.70 (0.58--0.82)       0.74 (0.62--0.84)          0.61 (0.42--0.77)                          0.001
   BO+LGD *vs* OAC                                                                                           0.39                                           811                      0.72 (0.56--0.84)       0.83 (0.65--0.94)          0.56 (0.38--0.72)                          0.003
  **Plasma ELISA for patients with a BMI of 18.5--29.9 kg m**^**−2**^ (***n*****=69)**                                                                                                                                                                         
   Non-malignant *vs* OAC                                                                                    0.63                                           811                      0.85 (0.76--0.95)       0.84 (0.64--0.95)          0.80 (0.65--0.90)                         \<0.001
   NE *vs* BO+LGD+OAC                                                                                        0.44                                           705                      0.77 (0.65--0.90)       0.69 (0.55--0.82)          0.75 (0.51--0.91)                         \<0.001
   BO+LGD *vs* OAC                                                                                           0.59                                           836                      0.83 (0.71--0.95)       0.76 (0.55--0.91)          0.83 (0.63--0.95)                         \<0.001

Abbreviations: AUC=area under the curve; BO=Barrett\'s oesophagus; BMI=body mass index; CI=confidence interval; OAC=oesophageal adenocarcinoma; ELISA=enzyme-linked immunosorbent assay; LGD=BO with low-grade dysplasia; MIC-1/GDF15=macrophage inhibitory cytokine 1/growth differentiation factor 15; NE=normal oesophagus/healthy controls; ROC=receiver operator characteristic.

Grouped as more *vs* less than the cutoff point generated by the ROC and Youden index; for relative gene expression no units apply for plasma measurements (pg ml^−1^).

*P*-value \<0.05 indicates that observed AUC is significantly different from 0.5 providing statistical evidence that the biomarker has the ability to distinguish between the two groups.

###### Univariable and multivariable Cox proportional hazards model for survival (*n*=27)

                                                **Univariable analysis**   **Multivariable analysis**                                 
  -------------------------------------------- -------------------------- ---------------------------- -------- ------- ------------- -------
   Age                                                    0.99                     0.95--1.04            0.82    1.04    0.98--1.11    0.23
   Body mass index                                        0.96                     0.84--1.10            0.59    0.99    0.85--1.15    0.88
   High tumour stage (III/IV)                             5.85                    1.92--17.85           0.0019   13.86   2.31--83.23   0.004
   MIC-1/GDF15 plasma levels ⩾1140 pg ml^−1^              2.91                     0.89--9.48           0.076    3.87    1.01--14.75   0.048

Abbreviations: CI=confidence interval; HR=hazard ratio; MIC-1/GDF15=macrophage inhibitory cytokine 1/growth differentiation factor 15.
